Vinorelbine for non-small cell lung cancer

Research output: Contribution to journalArticle

Abstract

Importance of the field: Vinorelbine is a 'third-generation' vinca alkaloid approved for the treatment of NSCLC. The introduction of 'third-generation' drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with substantially similar results among the different drugs. Treatment toxicities are considerable in this setting. Areas covered in this review: This narrative review reports a synthesis of evidence available from published clinical trials, systematic reviews and meta-analyses on the activity and safety of vinorelbine, used as single agent or in combination chemotherapy in patients with NSCLC, from 1990 to 2009. What the reader will gain: When vinorelbine was administered in a weekly schedule without interruptions, the most common toxicity was neutropenia that often precluded administration of the drug, therefore, reducing the dose intensity. A schedule providing administration of vinorelbine on days 1 and 8 every 3 weeks seemed to improve the tolerability of the drug. Tolerability of the drug did not result lower in the elderly subset. None of the other 'third-generation' drugs were clearly better tolerated than vinorelbine. Moreover, in the adjuvant setting, vinorelbine is the only third-generation drug that demonstrated, in combination with cisplatin, a consistent improvement in survival on a long-term basis. Take home message: Vinorelbine is an active and generally manageable therapeutic option for the treatment of both early and advanced NSCLC.

Original languageEnglish
Pages (from-to)493-510
Number of pages18
JournalExpert Opinion on Drug Safety
Volume9
Issue number3
DOIs
Publication statusPublished - May 2010

Fingerprint

Non-Small Cell Lung Carcinoma
Pharmaceutical Preparations
gemcitabine
Appointments and Schedules
Vinca Alkaloids
Taxoids
Survival
vinorelbine
Therapeutics
Combination Drug Therapy
Neutropenia
Platinum
Cisplatin
Meta-Analysis
Clinical Trials
Safety

Keywords

  • NSCLC
  • Platinum combinations
  • Safety
  • Third-generation drugs
  • Vinorelbine

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Vinorelbine for non-small cell lung cancer. / Piccirillo, Maria Carmela; Daniele, Gennaro; Di Maio, Massimo; Bryce, Jane; De Feo, Gianfranco; Del Giudice, Antonia; Perrone, Francesco; Morabito, Alessandro.

In: Expert Opinion on Drug Safety, Vol. 9, No. 3, 05.2010, p. 493-510.

Research output: Contribution to journalArticle

@article{2f0ba473721046818c1b32100370d9a0,
title = "Vinorelbine for non-small cell lung cancer",
abstract = "Importance of the field: Vinorelbine is a 'third-generation' vinca alkaloid approved for the treatment of NSCLC. The introduction of 'third-generation' drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with substantially similar results among the different drugs. Treatment toxicities are considerable in this setting. Areas covered in this review: This narrative review reports a synthesis of evidence available from published clinical trials, systematic reviews and meta-analyses on the activity and safety of vinorelbine, used as single agent or in combination chemotherapy in patients with NSCLC, from 1990 to 2009. What the reader will gain: When vinorelbine was administered in a weekly schedule without interruptions, the most common toxicity was neutropenia that often precluded administration of the drug, therefore, reducing the dose intensity. A schedule providing administration of vinorelbine on days 1 and 8 every 3 weeks seemed to improve the tolerability of the drug. Tolerability of the drug did not result lower in the elderly subset. None of the other 'third-generation' drugs were clearly better tolerated than vinorelbine. Moreover, in the adjuvant setting, vinorelbine is the only third-generation drug that demonstrated, in combination with cisplatin, a consistent improvement in survival on a long-term basis. Take home message: Vinorelbine is an active and generally manageable therapeutic option for the treatment of both early and advanced NSCLC.",
keywords = "NSCLC, Platinum combinations, Safety, Third-generation drugs, Vinorelbine",
author = "Piccirillo, {Maria Carmela} and Gennaro Daniele and {Di Maio}, Massimo and Jane Bryce and {De Feo}, Gianfranco and {Del Giudice}, Antonia and Francesco Perrone and Alessandro Morabito",
year = "2010",
month = "5",
doi = "10.1517/14740331003774078",
language = "English",
volume = "9",
pages = "493--510",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Vinorelbine for non-small cell lung cancer

AU - Piccirillo, Maria Carmela

AU - Daniele, Gennaro

AU - Di Maio, Massimo

AU - Bryce, Jane

AU - De Feo, Gianfranco

AU - Del Giudice, Antonia

AU - Perrone, Francesco

AU - Morabito, Alessandro

PY - 2010/5

Y1 - 2010/5

N2 - Importance of the field: Vinorelbine is a 'third-generation' vinca alkaloid approved for the treatment of NSCLC. The introduction of 'third-generation' drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with substantially similar results among the different drugs. Treatment toxicities are considerable in this setting. Areas covered in this review: This narrative review reports a synthesis of evidence available from published clinical trials, systematic reviews and meta-analyses on the activity and safety of vinorelbine, used as single agent or in combination chemotherapy in patients with NSCLC, from 1990 to 2009. What the reader will gain: When vinorelbine was administered in a weekly schedule without interruptions, the most common toxicity was neutropenia that often precluded administration of the drug, therefore, reducing the dose intensity. A schedule providing administration of vinorelbine on days 1 and 8 every 3 weeks seemed to improve the tolerability of the drug. Tolerability of the drug did not result lower in the elderly subset. None of the other 'third-generation' drugs were clearly better tolerated than vinorelbine. Moreover, in the adjuvant setting, vinorelbine is the only third-generation drug that demonstrated, in combination with cisplatin, a consistent improvement in survival on a long-term basis. Take home message: Vinorelbine is an active and generally manageable therapeutic option for the treatment of both early and advanced NSCLC.

AB - Importance of the field: Vinorelbine is a 'third-generation' vinca alkaloid approved for the treatment of NSCLC. The introduction of 'third-generation' drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with substantially similar results among the different drugs. Treatment toxicities are considerable in this setting. Areas covered in this review: This narrative review reports a synthesis of evidence available from published clinical trials, systematic reviews and meta-analyses on the activity and safety of vinorelbine, used as single agent or in combination chemotherapy in patients with NSCLC, from 1990 to 2009. What the reader will gain: When vinorelbine was administered in a weekly schedule without interruptions, the most common toxicity was neutropenia that often precluded administration of the drug, therefore, reducing the dose intensity. A schedule providing administration of vinorelbine on days 1 and 8 every 3 weeks seemed to improve the tolerability of the drug. Tolerability of the drug did not result lower in the elderly subset. None of the other 'third-generation' drugs were clearly better tolerated than vinorelbine. Moreover, in the adjuvant setting, vinorelbine is the only third-generation drug that demonstrated, in combination with cisplatin, a consistent improvement in survival on a long-term basis. Take home message: Vinorelbine is an active and generally manageable therapeutic option for the treatment of both early and advanced NSCLC.

KW - NSCLC

KW - Platinum combinations

KW - Safety

KW - Third-generation drugs

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=77951637766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951637766&partnerID=8YFLogxK

U2 - 10.1517/14740331003774078

DO - 10.1517/14740331003774078

M3 - Article

C2 - 20350282

AN - SCOPUS:77951637766

VL - 9

SP - 493

EP - 510

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 3

ER -